Insiders who acquired CN¥7.35m worth of Beauty Farm Medical and Health Industry Inc.’s (HKG:2373) stock at an average price of CN¥25.98 in the past 12 months may be dismayed by the recent 12% price decline. This is not good as insiders invest based on expectations that their money will appreciate over time. However, as a result of recent losses, their original investment is now worth only CN¥4.87m.
Although we don’t think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
The Last 12 Months Of Insider Transactions At Beauty Farm Medical and Health Industry
In the last twelve months, the biggest single purchase by an insider was when Non-Executive Director Fangyu Li bought HK$1.4m worth of shares at a price of HK$26.17 per share. So it’s clear an insider wanted to buy, even at a higher price than the current share price (being HK$17.21). Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it’s very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
While Beauty Farm Medical and Health Industry insiders bought shares during the last year, they didn’t sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for Beauty Farm Medical and Health Industry
SEHK:2373 Insider Trading Volume June 6th 2026
Beauty Farm Medical and Health Industry is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
Insiders At Beauty Farm Medical and Health Industry Have Bought Stock Recently
It’s good to see that Beauty Farm Medical and Health Industry insiders have made notable investments in the company’s shares. Specifically, Non-Executive Director Fangyu Li bought HK$985k worth of shares in that time, and we didn’t record any sales whatsoever. That shows some optimism about the company’s future.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. I reckon it’s a good sign if insiders own a significant number of shares in the company. It’s great to see that Beauty Farm Medical and Health Industry insiders own 32% of the company, worth about HK$1.4b. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Do The Beauty Farm Medical and Health Industry Insider Transactions Indicate?
It’s certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. When combined with notable insider ownership, these factors suggest Beauty Farm Medical and Health Industry insiders are well aligned, and quite possibly think the share price is too low. Looks promising! In addition to knowing about insider transactions going on, it’s beneficial to identify the risks facing Beauty Farm Medical and Health Industry. Case in point: We’ve spotted 1 warning sign for Beauty Farm Medical and Health Industry you should be aware of.
But note: Beauty Farm Medical and Health Industry may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Valuation is complex, but we’re here to simplify it.
Discover if Beauty Farm Medical and Health Industry might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.